Paul et al first demonstrated that mice deficient in Src were resistant to ischemic injury, and administration of Src inhibitors PP1 or PP2 to wild-type animals reduced ischemic injury in the brain [22–24]; Weis et al showed that the genetic or pharmacological blockade of Src reduced edema and tissue injury following myocardial infarction [24]. The gene discussed is SRC; the disease is myocardial infarction.